Equities researchers at BMO Capital Markets initiated coverage on shares of VBI Vaccines, Inc. (NASDAQ:VBIV) in a research note issued on Wednesday. The firm set an “outperform” rating and a $11.00 price target on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would suggest a potential upside of 143.90% from the company’s previous close.

A number of other research firms have also recently issued reports on VBIV. Noble Financial reaffirmed a “buy” rating on shares of VBI Vaccines in a report on Monday, July 31st. Zacks Investment Research cut VBI Vaccines from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. ValuEngine cut VBI Vaccines from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Finally, Canaccord Genuity assumed coverage on VBI Vaccines in a report on Wednesday, November 1st. They set a “buy” rating and a $10.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. VBI Vaccines currently has an average rating of “Hold” and an average target price of $10.50.

VBI Vaccines (NASDAQ VBIV) opened at $4.51 on Wednesday. The company has a current ratio of 2.00, a quick ratio of 1.91 and a debt-to-equity ratio of 0.18. VBI Vaccines has a twelve month low of $2.81 and a twelve month high of $6.60.

TRADEMARK VIOLATION WARNING: “VBI Vaccines, Inc. (VBIV) Now Covered by BMO Capital Markets” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.watchlistnews.com/vbi-vaccines-inc-vbiv-now-covered-by-bmo-capital-markets/1708581.html.

In other news, Director Steven Gillis acquired 300,000 shares of the company’s stock in a transaction on Monday, October 30th. The stock was purchased at an average cost of $3.05 per share, with a total value of $915,000.00. Following the acquisition, the director now owns 46,916 shares of the company’s stock, valued at approximately $143,093.80. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jeff Baxter acquired 10,000 shares of the company’s stock in a transaction on Monday, August 21st. The shares were purchased at an average cost of $3.22 per share, with a total value of $32,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 120,255 shares in the company, valued at approximately $387,221.10. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,068,738 shares of company stock valued at $12,411,711 over the last three months. Company insiders own 54.50% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Bank of Montreal Can grew its position in shares of VBI Vaccines by 8.6% during the 2nd quarter. Bank of Montreal Can now owns 63,398 shares of the biopharmaceutical company’s stock worth $277,000 after buying an additional 5,000 shares during the period. Cambridge Investment Research Advisors Inc. grew its position in shares of VBI Vaccines by 2.7% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 1,415,650 shares of the biopharmaceutical company’s stock worth $5,450,000 after buying an additional 37,660 shares during the period. California State Teachers Retirement System acquired a new position in shares of VBI Vaccines during the 2nd quarter worth about $167,000. Schwab Charles Investment Management Inc. acquired a new position in shares of VBI Vaccines during the 2nd quarter worth about $187,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of VBI Vaccines during the 2nd quarter worth about $193,000. Institutional investors own 20.38% of the company’s stock.

About VBI Vaccines

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.